During Wednesday’s Current trade, Shares of Westlake Chemical Corporation (NYSE:WLK), lost -1.08% to $63.34.
Westlake Chemical Corporation (WLK) declared recently that it has attained INEOS ChlorVinyls Holdings B.V.’s 35.7% interest in Suzhou Huasu Plastics Co., Ltd. (SHPC), a polyvinyl chloride (PVC) resin and downstream fabrication joint venture based near Shanghai, China. Westlake now owns a 95% interest in this joint venture.
SHPC operates a PVC resin production plant, together with specialty film and window profile operations.
Westlake Chemical Corporation manufactures and markets basic chemicals, vinyls, polymers, and fabricated building products. It operates through two segments, Olefins and Vinyls. The Olefins segment offers ethylene, polyethylene, styrene monomer, and various ethylene co-products, such as chemical grade propylene, crude butadiene, pyrolysis gasoline, and hydrogen.
Shares of Ameriprise Financial, Inc. (NYSE:AMP), declined -0.50% to $12.21, during its current trading session.
Ameriprise Financial, Inc. (AMP) released the results of the new Retirement 2.0SM study, revealing that the majority of Gen Xers (76%) report proactively planning for their retirement, with eight in 10 (79%) respondents presently saving through a 401(k) plan, and seven in 10 (69%) investing in an IRA or similar account.
The Retirement 2.0 study, which surveyed more than 1,500 Americans between the ages of 35-50 with at least $100,000 in investable assets, took a comprehensive look at how Gen X is approaching retirement. The study also explored how they have invested and saved for this major milestone; and how they expect to spend their retirement years. Encouragingly, the study found that Gen Xers began planning for retirement early and started saving at the average age of 26. They anticipate relying on their 401(k) accounts (42%) or IRAs (29%) as their main sources of income during retirement, while pensions (14%) and Social Security (5%) are predictable to take a back seat as primary sources of retirement funding.
Ameriprise Financial, Inc., through its auxiliaries, provides various financial products and services to individual and institutional clients in the United States and internationally. The company’s Advice & Wealth Administration segment provides financial planning and advice, in addition to full-service brokerage services primarily to retail clients through its advisors. Its Asset Administration segment offers investment advice and investment products to retail, high net worth, and institutional clients through unassociated third party financial institutions and institutional sales force. This segment’s products comprise U.S. mutual funds and their non-U.S. equivalents, exchange-traded funds, variable product funds underlying insurance, and annuity separate accounts; and institutional asset administration products, such as traditional asset classes, separately managed accounts, individually managed accounts, collateralized loan obligations, hedge funds, collective funds, and property funds.
AGCO Corporation (NYSE:AGCO), during its Wednesday’s current trading session decreased -1.38% to $53.50.
AGCO, Your Agriculture Company, (AGCO), a worldwide manufacturer and distributor of agricultural equipment, declared its 2015 Second Quarter Earnings Release Conference Call is planned for Tuesday, July 28th at 10:00 a.m. EDT.
AGCO Corporation manufactures and distributes agricultural equipment and related replacement parts worldwide. The company offers tractors, counting high horsepower tractors that are used on larger farms primarily for row crop production; utility tractors for small- and medium-sized farms, in addition to for specialty agricultural industries comprising dairy, livestock, orchards, and vineyards; compact tractors for small farms, specialty agricultural industries, landscaping, and residential uses; and combines used in harvesting grain crops, such as corn, wheat, soybean, and rice products.
Finally, Dyax Corp. (NASDAQ:DYAX), decreased -0.52%, to $26.67.
yax Corp. (DYAX) declared that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for the investigation of DX-2930 for hereditary angioedema (HAE). Dyax is developing DX-2930, an investigational fully human monoclonal antibody inhibitor of plasma kallikrein (pKal), as a subcutaneous injection for prevention of HAE attacks.
Breakthrough Therapy designation is intended to expedite the development and review of potential new medicines with early signal of clinical benefit in serious or life-threatening conditions and assists ensure patients have access to them as soon as possible. Breakthrough Therapy designation is considered when preliminary clinical evidence indicates the drug may demonstrate substantial improvement over accessible therapy. The benefits of Breakthrough Therapy designation comprise organizational commitment involving the FDA’s senior managers and with more intensive guidance. Breakthrough Therapy designation does not change the standards for approval.
Dyax Corp., a biopharmaceutical company, identifies, develops, and commercializes treatments for hereditary angioedema (HAE) and other plasma-kallikrein-mediated (PKM) disorders. It offers KALBITOR for the treatment of acute attacks of HAE. The company distributes KALBITOR through a network of wholesale, hospital, and specialty pharmacy arrangements. It is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b clinical study to treat HAE prophylactically.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
